Fermi Matteo, Lo Manto Alfredo, Lotto Cecilia, Cianci Giulia, Mattioli Francesco, Marchioni Daniele, Presutti Livio, Fernandez Ignacio Javier
Department of Otorhinolaryngology Head and Neck Surgery, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, 40138 Bologna, Italy.
Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum, Università di Bologna, 40126 Bologna, Italy.
J Clin Med. 2023 Mar 14;12(6):2261. doi: 10.3390/jcm12062261.
Horizontal glottectomy (HG) is a particular type of partial laryngectomy indicated for exclusive glottic tumor with anterior commissure involvement. The purpose of this study is to systematically review the literature about functional and oncological outcome of HG. This systematic review adhered to the recommendations of the PRISMA (Preferred Reporting Items of Systematic Reviews and Meta-analysis) 2009 guidelines. Articles mentioning patients undergoing HG for laryngeal squamous cell carcinoma were included. A total of 14 articles were selected and reviewed from 19 identified. The whole study population consisted of 420 patients who underwent HG. Three hundred and thirty-nine patients out of 359 were staged as T1. The range of post-operative follow-up was 5 months to 10 years. Fifty-five recurrences were experienced, being local, regional and distant in 35, 12 and 8 patients, respectively. Laryngeal preservation rate was 93.6%. Nasogastrict tube was removed on average after 10.1 days. The tracheostomy was maintained for 11.3 days. Mean hospitalization lasted for 11.7 days. According to the results of this systematic review, HG is an oncologically safe surgical option for T1a-T1b glottic tumors with oncological outcomes comparable to other treatment. HG could be a good therapeutical choice whenever poor laryngeal exposure and/or patient's refusal of radiotherapy are encountered, or when patient's medical history represents a contraindication for radiation therapy.
水平喉切除术（HG）是一种特殊类型的部分喉切除术，适用于仅累及声门且侵犯前联合的肿瘤。本研究的目的是系统回顾关于HG的功能和肿瘤学结局的文献。本系统评价遵循了2009年PRISMA（系统评价和Meta分析的首选报告项目）指南的建议。纳入提及接受HG治疗喉鳞状细胞癌患者的文章。从19篇已识别的文章中筛选并回顾了14篇文章。整个研究人群包括420例接受HG治疗的患者。359例患者中有339例分期为T1。术后随访时间为5个月至10年。共发生55例复发，其中局部复发35例，区域复发12例，远处复发8例。喉保留率为93.6%。鼻胃管平均在10.1天后拔除。气管造口术维持11.3天。平均住院时间为11.7天。根据本系统评价的结果，HG对于T1a-T1b声门肿瘤是一种肿瘤学上安全的手术选择，其肿瘤学结局与其他治疗方法相当。当遇到喉部暴露不佳和/或患者拒绝放疗，或患者病史为放疗禁忌证时，HG可能是一个很好的治疗选择。
